Evidence map›Paper›PMID 34362694›Full record

ArticleClinical genitourinary cancer2021

Impact of Histology and Tumor Grade on Clinical Outcomes Beyond 5 Years of Follow-Up in a Large Cohort of Renal Cell Carcinomas.

Manuela Costantini, Maria Luana Poeta, Ruth M Pfeiffer, Dana Hashim, Catherine L Callahan, Steno Sentinelli, Laura Mendoza, Marco Vicari, Vincenzo Pompeo, Angela Cecilia Pesatori and 5 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Manuela CostantiniDepartment of Urology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy.
Maria Luana PoetaDepartment of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy.
Ruth M PfeifferDivision of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD.
Dana HashimDepartment of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Catherine L CallahanDivision of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD.
Steno SentinelliDepartment of Pathology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy.
Laura MendozaDivision of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD.
Marco VicariLaboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Italy.
Vincenzo PompeoDepartment of Urology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy.
Angela Cecilia PesatoriDepartment of Clinical Sciences and Community Health, Università degli Studi di Milano and Fondazione IRCCS - Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Curt T DellaValleDivision of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD.
Giuseppe SimoneDepartment of Urology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy.
Vito Michele FazioLaboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano and Fondazione IRCCS - Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Laboratory of Oncology, IRCCS H. "Casa Sollievo della Sofferenza", San Giovanni Rotondo (FG), Italy.
Michele GallucciDepartment of Urology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy; Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy; Division of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD; Department of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Pathology, IRCCS- Regina Elena National Cancer Institute, Rome, Italy; Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano and Fondazione IRCCS - Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Laboratory of Oncology, IRCCS H. "Casa Sollievo della Sofferenza", San Giovanni Rotondo (FG), Italy; Department of Urology, Sapienza University, Rome, Italy.
Maria Teresa LandiDivision of Cancer Epidemiology Genetics, National Cancer Institute, NIH, Bethesda, MD. Electronic address: landim@mail.nih.gov.
Istituti di Ricovero e Cura a Carattere Scientifico · ITNational Cancer Institute · USUniversità Campus Bio-Medico · ITIcahn School of Medicine at Mount Sinai · USNational Institutes of Health · USUniversity of Bari Aldo Moro · ITUniversity of Milan · IT

Funding

Studies of Genetic and Environmental EpidemiologyZIACP101231 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI LANDI, MARIA · 2018 to 2025
$23.6M
Intramural NIH HHS ZIA CP101231
6 · The paper itself

Abstract

introductionThe optimal length for clinical follow-up of renal cell carcinoma (RCC) patients is unclear. We evaluated the impact of ISUP/WHO tumor grade and histological subtype on short- and long-term survival and risk of recurrence/metastasis in a large cohort of RCC patients. PATIENTS AND

methodsWe studied 1679 RCC patients from a single referral center in Italy. Adjusted hazard ratios for overall survival were estimated using Cox regression models. Adjusted absolute risk of developing recurrence or metastasis was computed considering competing risks of mortality.

resultsDuring up to 13 years of follow-up, 175 (10.4%) RCC patients died, of whom 92% beyond 5 years. Hazard ratio of grade IV clear cell carcinomas (ccRCC) was 3.82 compared to grade II. Notably, 33% of recurrences and 56% of distant metastases occurred beyond 5 years of follow-up. The estimated probabilities of recurrence/metastasis were 15% and 45% within and beyond 5 years of follow-up, respectively. After 5 years, the absolute risk of recurrences increased also for papillary renal cell carcinoma type I (35.2%) and grade I ccRCC (17%).

conclusionAfter 5 years of follow-up, both risk of mortality and recurrences or metastases were high and were modified by histological types and tumor grade. These data strongly support histology- and grade-tailored surveillance strategies and long-term follow-up for RCC patients.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCohort StudiesFollow-Up StudiesHumansNeoplasm Recurrence, LocalAbsolute riskHistologyRecurrenceRenal cell carcinomaSurveillance

Identifiers

PMID34362694
PMCPMC8490324
OpenAlexW3182152656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.